Invivyd, Inc., a biopharmaceutical company, has announced significant changes to its executive team. Jeremy Gowler has stepped down from his roles as Interim Chief Executive Officer, Chief Operating Officer, and Chief Commercial Officer, effective May 30, 2024. His employment with the company will terminate on June 29, 2024. In the interim, William Duke, Jr., who has been the company's Chief Financial Officer since September 2023, will take over as the Principal Executive Officer while also continuing his duties as the CFO. The Board of Directors is actively searching for a permanent CEO. Additionally, Invivyd has appointed Timothy Lee as the new Chief Commercial Officer, a move aimed at bolstering the company's commercial capabilities, particularly for the launch of PEMGARDA, their commercial phase asset...Show More

Invivyd, Inc., a biopharmaceutical company, has announced significant changes to its executive team. Jeremy Gowler has stepped down from his roles as Interim Chief Executive Officer, Chief Operating Officer, and Chief Commercial Officer, effective May 30, 2024. His employment with the company will terminate on June 29, 2024. In the interim, William Duke, Jr., who has been the company's Chief Financial Officer since September 2023, will take over as the Principal Executive Officer while also continuing his duties as the CFO. The Board of Directors is actively searching for a permanent CEO. Additionally, Invivyd has appointed Timothy Lee as the new Chief Commercial Officer, a move aimed at bolstering the company's commercial capabilities, particularly for the launch of PEMGARDA, their commercial phase asset. Invivyd has also announced alignment with the FDA on an immunobridging pathway for potential emergency use authorizations for novel monoclonal antibodies for COVID-19 prevention and treatment. The company's proprietary INVYMAB platform is designed to rapidly generate new monoclonal antibodies to address evolving viral threats, with PEMGARDA being the first in a planned series of antibody candidates.